Premier Alternatives

XyloCor Therapeutics

King of Prussia, PA · Founded 2013 · Privately Held (backing)

Operator of a bio-pharmaceutical firm intended to develop gene therapy for people with advanced coronary artery disease. XyloCor Therapeutics is based in King of Prussia, PA and was founded in 2013. It was valued at $130 million at its later-stage round in Jan 2025, the last priced event on record. It has raised $122 million across 3 recorded rounds; the latest was a $4 million seed round in Jan 2021.

PMV mark · valuation
$130.0M
Oct 2026
Priced at
its later-stage round
Jan 2025
Total raised
$122.0M
Last round
Seed Round
Jan 2021

XyloCor Therapeutics key facts

as of Oct 2026
  • Operator of a bio-pharmaceutical firm intended to develop gene therapy for people with advanced coronary artery disease.
  • XyloCor Therapeutics is valued at approximately $130.0M as of Oct 2026, set at its later-stage round, Jan 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $122.0M across 3 recorded rounds; the latest was Seed Round ($4.0M) in Jan 2021.
  • Notable investors include EQT Life Sciences, Cornell University, Fountain Healthcare Partners, Jeito, Longwood Fund — 8 tracked in total.
  • XyloCor Therapeutics has filed 6 Form Ds with the SEC since 2016, most recently Jan 2021 ($4.0M sold to 5 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$130.0M

Valued at $130.0M at its later-stage round, Jan 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of XyloCor Therapeutics with a free account
  • ·Watch XyloCor Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

XyloCor Therapeutics funding rounds

3 rounds
Jan 2021Seed Round$4.0MSEC filing▮
Oct 2018Early Stage VC$16.8MSEC filing▮
Nov 2016Debt$250KSEC filing▮
Full funding history →

XyloCor Therapeutics valuation

XyloCor Therapeutics was valued at $130 million at its later-stage round in Jan 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has XyloCor Therapeutics raised?

XyloCor Therapeutics has raised $122 million in total; 3 of its rounds are on record, from 2016 on. The largest on record was a $4 million seed round in Jan 2021.

XyloCor Therapeutics has filed 6 Form Ds with the SEC since 2016, most recently in Jan 2021 ($4 million sold to 5 investors).

XyloCor Therapeutics investors

8 investors are on record for XyloCor Therapeutics, including EQT Life Sciences, Cornell University, Fountain Healthcare Partners and Jeito. The seed round in Jan 2021 drew 5 investors.

About XyloCor Therapeutics

Operator of a bio-pharmaceutical firm intended to develop gene therapy for people with advanced coronary artery disease. The company's firm focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patients with refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost-effectively.

Sector
Healthcare
HQ
King of Prussia, PA, United States
Founded
2013
Employees
16
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.